Goldman Sachs starts Stedim shares at "buy", sees more than 20% upside potential By Investing.com
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 03 2024
0mins
Source: Investing.com
Goldman Sachs Coverage Initiation: Goldman Sachs has given Sartorius Stedim Biotech a "buy" rating with a 12-month price target of €225, citing its strong position in the bioprocessing market and favorable valuation compared to its parent company, Sartorius AG.
Market Recovery Outlook: Analysts predict a gradual recovery for Sartorius Stedim post-pandemic, with expectations of double-digit revenue growth after 2025, driven by increasing demand for biologic drugs and improvements in operational dynamics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
